^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    varlitinib (ASLAN001)

    i
    Company:
    ASLAN Pharma, Blade Entertaintment, Pfizer
    Drug class:
    EGFR inhibitor, HER2 inhibitor, HER4 inhibitor
    Related drugs:
    Apply
    Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients (NCT05400915)
    Phase 1/2
    Yonsei University
    Completed
    Last update posted :
    11/10/2023
    Initiation :
    07/23/2019
    Primary completion :
    12/13/2021
    Completion :
    06/13/2022
    EGFR • HER-2
    |
    EGFR mutation • HER-2 amplification • HER-2 expression • EGFR amplification • EGFR expression
    |
    paclitaxel • varlitinib (ASLAN001)
    Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) (NCT03130790)
    Phase 2/3
    Aslan Pharmaceuticals
    Completed
    Last update posted :
    02/15/2022
    Initiation :
    08/31/2017
    Primary completion :
    12/20/2018
    Completion :
    02/22/2019
    HER-2
    |
    HER-2 overexpression • HER-2 amplification
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • varlitinib (ASLAN001)
    ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin (NCT02435927)
    Phase 1
    National Cancer Centre, Singapore
    Active, not recruiting
    Last update posted :
    04/28/2021
    Initiation :
    08/01/2014
    Primary completion :
    06/01/2021
    Completion :
    06/01/2021
    EGFR • HER-2
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • varlitinib (ASLAN001)
    A Study of ARRY-334543 in Patients With Advanced Cancer (NCT00278902)
    Phase 1
    Array Biopharma, now a wholly owned subsidiary ...
    Completed
    Last update posted :
    10/14/2020
    Initiation :
    01/01/2006
    Primary completion :
    06/01/2009
    Completion :
    06/01/2009
    HER-2
    |
    varlitinib (ASLAN001)
    Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer (NCT03129074)
    Phase 2
    Aslan Pharmaceuticals
    Withdrawn
    Last update posted :
    05/23/2018
    Initiation :
    05/01/2018
    Primary completion :
    03/01/2020
    Completion :
    09/01/2020
    HER-2
    |
    EGFR mutation
    |
    capecitabine • varlitinib (ASLAN001)
    Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC) (NCT03499626)
    Phase 1b
    National University Hospital, Singapore
    Unknown status
    Last update posted :
    04/17/2018
    Initiation :
    05/05/2017
    Primary completion :
    05/05/2019
    Completion :
    05/05/2021
    ERBB3
    |
    ERBB3 expression
    |
    sorafenib • Lenvima (lenvatinib) • varlitinib (ASLAN001)
    Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer (NCT02396108)
    Phase 2
    National University Hospital, Singapore
    Unknown status
    Last update posted :
    02/03/2017
    Initiation :
    03/01/2015
    Primary completion :
    03/01/2018
    Completion :
    03/01/2019
    HER-2
    |
    HER-2 positive • HER-2 amplification
    |
    carboplatin • paclitaxel • varlitinib (ASLAN001)